Conference Coverage
Conference Coverage
Should McDonald criteria include optical nerve lesions?
Researchers come out in favor, with a caveat against misdiagnoses.
Conference Coverage
Stem cell transplantation ‘substantially’ superior to fingolimod in cutting MS relapse risk
AHSCT is substantially superior to fingolimod and marginally superior to natalizumab in reducing the risk of posttreatment relapses.
News
Higher cardiovascular fitness may help preserve mobility in MS
Cardiorespiratory fitness “may exert neuroprotective effects on the central nervous system.”
Conference Coverage
High-efficacy therapies for MS: When and how to use them
Experts make the case for use of high-efficacy therapies in MS.
Conference Coverage
Cognitive impairment may predict physical disability in MS
Clinicians should consider testing cognitive processing speed in patients with MS to identify those who are at increased risk for disease...
Conference Coverage
Risk of drug interactions is on the rise as MS drugs evolve
Newer medications pose more danger, pharmacist says, and require more awareness.
Conference Coverage
Consider the wider picture in relapsing remitting MS
The best medication for a patient may not have highest efficacy, one expert says.
Conference Coverage
Inebilizumab beneficial across genotypes in NMOSD
"These data illustrate how mechanistic precision in treatment design can help patients gain benefit from their regimen regardless of the genetic...
Conference Coverage
Stem cell transplants for MS are a ‘reasonable option,’ but questions persist
Costly procedures help some patients but where to draw the line is unclear.
Conference Coverage
MS and COVID-19: Conflicting signs on risk but some trends are clearer
Patients on certain DMTs seem to fare worse and careful timing of vaccination is advisable.